Avior Wealth Management LLC Acquires 645 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Avior Wealth Management LLC grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 9.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,822 shares of the biotechnology company’s stock after buying an additional 645 shares during the quarter. Avior Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $985,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Sequoia Financial Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at about $732,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Ascendis Pharma A/S by 1.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company’s stock valued at $1,762,000 after purchasing an additional 186 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ascendis Pharma A/S by 353.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,635 shares of the biotechnology company’s stock valued at $836,000 after purchasing an additional 5,173 shares during the period. Legato Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at about $204,000. Finally, TimesSquare Capital Management LLC raised its holdings in shares of Ascendis Pharma A/S by 9.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 842,801 shares of the biotechnology company’s stock valued at $78,920,000 after purchasing an additional 75,374 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 1st. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Finally, Wedbush increased their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.25.

Ascendis Pharma A/S Stock Up 0.5 %

Shares of NASDAQ:ASND opened at $142.17 on Thursday. The company’s 50 day moving average price is $149.17 and its two-hundred day moving average price is $123.75. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00. The firm has a market cap of $8.28 billion, a PE ratio of -15.37 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.19 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.